Synthesis and antiviral bioactivity of novel (1E, 4E)-1-aryl-5-(2-(quinazolin-4-yloxy)phenyl)-1,4-pentadien-3-one derivatives

A series of novel (1E, 4E)-1-aryl-5-[2-(quinazolin-4-yloxy)phenyl]-1,4-pentadien-3-one derivatives were designed and synthesized by reacting substituent aldehyde with intermediates 4a–f. Antiviral bioassays indicated that most of the compounds exhibited promising ex vivo antiviral bioactivities against tobacco mosaic virus (TMV) and cucumber mosaic virus (CMV) at 500 μg/mL. The relationship between structure and antiviral activity was also discussed. Compounds 5a, 6e, and 6g could possess appreciable protective bioactivities on TMV ex vivo by approximately 50% (EC50) at 257.7, 320.7 and 243.3 μg/mL. This study is the first to demonstrate that (1E, 4E)-1-aryl-5-(2-(quinazolin-4-yloxy)phenyl)-1,4-pentadien-3-one can be used to develop potential virucides for plants.

The (1E, 4E)-1-aryl-5-(2-(quinazolin-4-yloxy)phenyl)penta-1,4-dien-3-one were synthesized. The compounds were screened for their antiviral activities.Figure optionsDownload as PowerPoint slideHighlights
► A series of novel (1E, 4E)-1, 4-pentadien-3-one derivatives were synthesized.
► The antiviral activity of the new compounds were tested ex vivo.
►  Compounds 5a, 6e, and 6g showed potent antiviral activity.